Can GLP-1 agonists improve heart function?
GLP-1 agonists, and in particular semaglutide and tirzepatide, demonstrably reduce the risk of heart failure worsening in people with a specific form of heart failure; if you have this condition or type 2 diabetes, discuss with your cardiologist whether these agents are appropriate for you.
In people with heart failure in whom the pumping function is still reasonably preserved (a form that is difficult to treat), GLP-1 agonists reduce the risk of heart failure worsening by approximately 40 to 44 percent. The combined risk of cardiovascular death or worsening also falls by around 30 to 32 percent. This has been demonstrated across multiple randomised studies together, involving nearly nine thousand patients.
Semaglutide is the most studied agent in this context. In an analysis of four large trials involving more than three thousand people with this type of heart failure, semaglutide had fewer serious side effects than placebo: they occurred in 30 percent of semaglutide users, compared with 39 percent in the placebo group. Tirzepatide, an agent that targets two hormone receptors simultaneously, also showed a significant reduction in both cardiovascular death and heart failure worsening in a double-blind study of 731 people with heart failure and obesity (a BMI of 30 or higher), along with improved quality of life after one year.
In people with type 2 diabetes, GLP-1 agonists also reduce the risk of serious cardiovascular events such as a heart attack or stroke. This has been demonstrated in multiple large cardiovascular outcomes studies.
On one point the effect is less convincing: cardiovascular mortality as a standalone outcome does not decline significantly. The benefit is therefore primarily about preventing worsening and hospitalisations, and not demonstrably about fewer deaths from heart problems.
Exactly how GLP-1 agonists act on the heart is not yet fully understood. They simultaneously improve weight, blood pressure, blood sugar and inflammatory markers, which likely explains a large part of the cardiac benefit. Whether there is also a direct effect via receptors on heart muscle cells, blood vessels and immune cells is still being investigated.
The evidence for improvement of heart failure with preserved pumping function rests on multiple large randomised studies, summarised in a systematic review with meta-analysis and a pooled analysis of four trials. For the effect in type 2 diabetes, several separate large cardiovascular outcomes studies are available. The researchers themselves conclude that cardiovascular mortality as a standalone endpoint does not decline significantly, which is an important caveat. The mechanisms underlying the cardiac protection have not yet been fully elucidated, and research into them currently rests on smaller and more indirect findings.
Do GLP-1 medications cause suicidal thoughts?
The available research gives no indication that GLP-1 medications cause suicidal thoughts; several large studies actually point to a lower risk. If you have doubts or concerns, discuss them with your doctor.
What are the benefits and risks of microneedling?
Microneedling is best supported by evidence for atrophic acne scars, with consistent positive results across multiple randomised studies. For other skin concerns the indications are promising but less certain, and those with darker skin tones would be wise to discuss the risk of dark spots with a dermatologist beforehand.
What health benefits do GLP-1 medications offer beyond weight loss?
In type 2 diabetes, GLP-1 medications offer well-supported protection for the heart, blood vessels, and kidneys; there are also preliminary indications of effects on the liver and brain, but these are too early to act on.
Do GLP-1 medications (such as Ozempic) help you age more healthily?
For people with cardiovascular disease, kidney disease, or fatty liver disease, GLP-1 medications offer proven benefits that are also relevant at older ages. As an anti-ageing intervention in healthy people, their use is not yet supported by evidence.